Two chemotherapy sequences for elderly double expressor DLBCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new sequence of two chemotherapy regimens (RLC followed by CR-CHOP) for elderly patients with a fast-growing DLBCL called double expressor lymphoma. The goal is to see if this approach is safe and effective for people who may not tolerate standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with untreated DLBCL (a type of lymphoma).
- Your biopsy must show high levels of both MYC and BCL2 proteins (called 'double expressor').
- You are over 70, or at least 65 with some difficulty in daily activities (ECOG 2+).
- You have at least one tumor that can be measured (a lymph node >1.5 cm or other tumor >1 cm).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This Phase 2 study tests a treatment sequence for people with high-risk diffuse large B-cell lymphoma (DLBCL) that includes loncastuximab plus rituximab, then DA-EPOCH-R. It aims to improve responses in patients whose lymphoma has specific high-risk features.
This study tests a “mini-CHOP-like” chemotherapy plan for newly diagnosed diffuse large B-cell lymphoma (DLBCL) in people age 70 and older. It may help you learn whether this gentler regimen works well and is safe in older adults who are newly starting treatment.
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
This trial compares two different shortened treatment schedules of R-CHOP to see which one is safer and works better for people with low-risk diffuse large B-cell lymphoma (DLBCL). It aims to reduce risk from treatment while maintaining strong cancer control after an initial response.
Hear when a new Double Expressor Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.